



PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

Date: 30.05.2019

To
National Stock Exchange of India Limited
Exchange Plaza
Plot No. C/1, G Block
Bandra Kurla Complex
Bandra (E), Mumbai- 400051

To
Bombay Stock Exchange Limited
Phiroze Jejeebhoy Towers
Rotund Bldg., Dalal Street
Mumbai- 400051

SYMBOL: PDPL

Scrip Code: 524689

Subject: Submission of Audited Financial Results for the Quarter and Financial year ended on 31st March, 2019


Dear Sir/Madam

Pursuant to the provisions of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith, the Audited Financial Results (Standalone and Consolidated basis) as on 31st March, 2019 of the Company along with the Independent Audit Report given by the Statutory Auditors of the Company on the Audited Financial Statements for the year ended on 31st March, 2019 and declaration under Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for the information of the Exchange and Members thereof.

You are requested to take the same on record.

Thanking You
For Parenteral Drugs (India) Limited


Suruchi Maheshwari
Company Secretary



Attached: As above



PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office : 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (W), Mumbai

AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON 31ST MARCH, 2019

(Rs in Lakh, unless otherwise stated)

| Sr. No. | Particulars | Quarter Ended 31-03-2019 (Audited) | Quarter Ended 31-12-2018 (Unaudited) | Quarter Ended 31-03-2018 (Audited) | Year Ended 31-03-2019 (Audited) | Year Ended 31-03-2018 (Audited) |
|---------|--|--|--|--|---------------------------------------|---------------------------------------|
| | Refer Notes below | | | | | |
| | Income | | | | | |
| I | (a) Revenue From Operation (Including excise duty) | 239.07 | 1,017.90 | 513.46 | 3,202.78 | 3,297.13 |
| II | (b) Other Operating Income | 139.91 | 0.27 | 17.33 | 143.52 | 134.41 |
| III | Total Income (I+II) | 378.98 | 1,018.17 | 530.79 | 3,346.30 | 3,431.54 |
| IV | Expenditure | | | | | |
| | Cost of Material Consumed | 6.33 | 273.79 | 85.90 | 757.17 | 439.20 |
| | Purchase of Stock In Trade | | | 23.63 | | 131.15 |
| | Change in Inventories of Finished Goods, Stock In trade and Work In Progress | 60.10 | (48.85) | (22.10) | (111.15) | 105.82 |
| | Employee Benefit Expenses | 536.13 | 469.63 | 478.98 | 1,994.02 | 1,669.69 |
| | Finance costs | 2,490.61 | 2,443.44 | 2,220.04 | 9,605.44 | 8,634.00 |
| | Depreciation, Amortisation and Impairment Expenses | 5,520.18 | 463.43 | 499.47 | 6,911.93 | 1,856.65 |
| | Other Expenditure | 563.09 | 549.66 | 491.16 | 2,328.39 | 2,535.30 |
| | Total Expenses (IV) | 9,176.44 | 4,151.10 | 3,777.09 | 21,485.80 | 15,371.81 |
| V | Profit / (Loss) before exceptional items and Tax (I-IV) | (8,797.46) | (3,132.93) | (3,246.30) | (18,139.50) | (11,940.27) |
| VI | Exceptional items | - | - | - | - | - |
| VII | Profit / (Loss) before Tax (V-VI) | (8,797.46) | (3,132.93) | (3,246.30) | (18,139.50) | (11,940.27) |
| VIII | Tax Expenses (1) Current Tax (2) Deferred Tax | (1,601.65) | (608.30) | (516.88) | (3,349.06) | (2,331.05) |
| IX | Net Profit / (Loss) for the period from continuing operations (VII-VIII) | (7,195.81) | (2,524.63) | (2,729.42) | (14,790.44) | (9,609.22) |
| X | Net Profit / (Loss) for the period from discontinuing operations | | | | | |
| XI | Tax expense of discontinuing operations | | | | | |
| XII | Net Profit / (Loss) from discontinued operations (after Tax) (X-XI) | | | | | |
| XIII | Profit/(loss) for the period (IX+XII) | (7,195.81) | (2,524.63) | (2,729.42) | (14,790.44) | (9,609.22) |
| XIV | Other Comprehensive Income | | | | | |
| | A (i) Item that will not be reclassified to Profit or loss (ii) Income tax relation to Item that will not be reclassified to Profit or loss | (21.80) | (1.09) | 61.23 | (25.07) | (2.31) |
| | B (i) Item that will be reclassified to Profit or loss (ii) Income tax relation to Item that will be reclassified to Profit or loss | | | | | |
| XV | Total comprehensive Income for the period (XIII+XIV)(comprising profit (loss) and other comprehensive income for the period) | (7,217.61) | (2,525.72) | (2,668.19) | (14,815.51) | (9,611.53) |
| XVI | Paid Up Equity share capital(Face value Rs.10/-each) | 2,981.63 | 2,981.63 | 2,981.63 | 2,981.63 | 2,981.63 |
| XVII | Earnings per share (for continuing operation) : | | | | | |
| | (a) Basic (In Rs) | (24.13) | (8.47) | (9.15) | (49.61) | (32.24) |
| | (b) Diluted (In Rs) | (24.13) | (8.47) | (9.15) | (49.61) | (32.24) |
| XVIII | Earnings per share (for discontinued operation) : | | | | | |
| | (a) Basic (In Rs) | | | | | |
| | (b) Diluted (In Rs) | | | | | |
| XIX | Earnings per share (for discontinued & continuing operation) : | | | | | |
| | (a) Basic (In Rs) | (24.13) | (8.47) | (9.15) | (49.61) | (32.24) |
| | (b) Diluted (In Rs) | (24.13) | (8.47) | (9.15) | (49.61) | (32.24) |



Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing,
Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03;
Fax: (0731) 2401052; E-mail: pdpl@pdindia.com;
CIN: L24100MH1983PLC126481



DRS is Accredited by
JAS-ANZ M50809121F

JAS-ANZ



www.jas-anz.org/register




PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

Statement of Assets and Liabilities (STANDALONE)

(Rs in Lakh)

| Sr. No. | Particulars | As at 31-03-19 Audited | As at 31-03-18 Audited |
|------------|--|---------------------------|---------------------------|
| I. | ASSETS | | |
| (1) | Non-current assets | | |
| | (a) Property, plant and equipment | 35,648.65 | 61,692.39 |
| | (b) Intangible assets | | |
| | (c) Financial Assets | | |
| | (i) Investments | 257.85 | 257.85 |
| | (ii) Loans | 255.25 | 258.50 |
| | (ii) Others | 1.32 | 4.84 |
| | (d) Other non-current assets | 559.88 | 567.52 |
| | (e) Deferred tax Assets(Net) | 10,534.86 | 7,176.99 |
| | Total Non-current assets | 47,257.81 | 69,958.09 |
| (2) | Current assets | | |
| | (a) Inventories | 397.06 | 124.85 |
| | (b) Financial Assets | | |
| | (i) Investments | | 36.89 |
| | (ii) Trade receivables | | 0.66 |
| | (iii) Cash and cash equivalents | 9.43 | |
| | (iv) Bank balances ther than (iii) above | 35.10 | 76.86 |
| | (v) Loans | 512.23 | 496.62 |
| | (c) Other Current Assets | 5,704.03 | 5,738.64 |
| | Total Current assets | 6,657.85 | 6,474.52 |
| | Total Assets | 53,915.66 | 76,432.61 |
| II. | EQUITY AND LIABILITIES | | |
| | Equity | | |
| | (a) Equity share capital | 2,981.63 | 2,981.63 |
| | (b) Other Equity | (47,706.52) | (13,759.21) |
| | Total Equity | (44,724.89) | (10,777.58) |
| (1) | LIABILITIES | | |
| | Non-Current Liabilities | | |
| | (a) Financial Liabilities | | |
| | (i) Borrowings | 10,871.05 | 34,051.54 |
| | (ii) Other financial liabilities | - | - |
| | (b) Other non-current liabilities | 15.00 | 16.50 |
| | Total Non-Current Liabilities | 10,886.05 | 34,068.04 |
| (2) | Current liabilities | | |
| | (a) Financial Liabilities | | |
| | (i) Borrowings | | 12,793.54 |
| | (ii) Trade payables | 1,186.97 | 1,357.40 |
| | (iii) Other financial liabilities | 80,695.43 | 35,278.68 |
| | (b) Other current liabilities | 5,034.44 | 2,987.11 |
| | (c) Provisions | 837.67 | 725.42 |
| | Total Current liabilities | 87,754.51 | 53,142.15 |
| | Tota Equity and Liabilities | 53,915.67 | 76,432.61 |



Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing,
Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03;
Fax: (0731) 2401052; E-mail: pdpl@pdindia.com;
CIN: L24100MH1983PLC126481



DRS is Accredited by
JAS-ANZ M50809121F

JAS-ANZ



www.jas-anz.org/register



PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com


Notes to the financial results:

- 1 The above results were reviewed by statutory auditors and audit committee of the company held on 29-05-2019 and approved by Board of Directors in their meeting held on 30-05-2019.
- 2 The above standalone financial results for the quarter and year ended 31 st MARCH 2019 have been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable beginning April 1, 2017.
- 3 Pursuant to valuation of the assets(land and building) of erstwhile manufacturing units of the company located at village Asrawad ,Indore (MP)and village Bhud,Tahasil Nalagarh,Baddi (HP), the impairment losses for the building situated at Asrawad have been booked for Rs51.74 crores and for the land located at Asrawad revaluation reserve reduced by Rs.191.32 crores .
- 4 The figures for the quarter ended March 31, 2019 and March 31, 2018 are the balancing figures between audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevant financial year.
- 5 At the moment the Company is having only one reportable segment in accordance with Ind AS 108 (segment reporting) as the business under proposed real estate segment is yet to commence.
- 6 The previous period figures have been regrouped/rearranged wherever found necessary.
- 7 The Standalone financial results of the Company are available on the web site of the company i.e. www.pdindia.com and on website of the BSE (www.bseindia.com) & NSE (www.nseindia.com)

Place: Indore

Date: 30-05-2019

For & on behalf of the Board of Directors


GOVIND DAS GARG
Director
DIN 00520067





Independent Auditor's Report on Standalone Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

The Board of Directors of Parenteral Drugs (India) Limited

1. We have audited the standalone financial results of Parenteral Drugs (India) Limited ('the Company') for the year ended 31 March 2019, being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These standalone financial results are based on the standalone financial statements for the year ended 31st March 2019 prepared in accordance with the accounting principles generally accepted in India, including Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 ('the Act') and published standalone year to date figures up to the end of the third quarter of the financial year prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, Interim Financial Reporting, specified under Section 133 of the Act, and SEBI Circulars CIR/CFD/FAC/62/2016 dated 5th July 2016 and CIR/IMD/DF1/69/2016 dated 10 August 2016, which are the responsibility of the Company's management. Our responsibility is to express an opinion on these standalone financial results based on our audit of the standalone financial statements for the year ended 31st March 2019 and our review of standalone financial results for the nine months period ended 31st December 2018.
2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.
3. In our opinion and to the best of our information and according to the explanations given to us, the standalone financial results: (i) are presented in accordance with the requirements of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circulars CIR/CFD/FAC/62/2016 dated 5 July 2016 and CIR/IMD/DF1/69/2016 dated 10 August 2016 in this regard; and (ii) give a true and fair view of the standalone net profit (including other comprehensive income) and other financial information in conformity with the accounting principles generally accepted in India including Ind AS specified under Section 133 of the Act for the year ended 31 March 2019.

For Singhal Jain & Co.
Chartered Accountants



Kamal Jain

Place: Indore
Date: 30.05.2019

CA Kamal Jain
(Partner)
M. No. 406604
F.R.N.013995C



PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office : 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (W), Mumbai

AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON 31ST MARCH, 2019

| Sr. No. | Particulars | (Rs in Lakh, unless otherwise stated) | | | | |
|---------|---|--|--|--|---------------------------------------|---------------------------------------|
| | | Quarter Ended 31-03-2019 (Audited) | Quarter Ended 31-12-2018 (Unaudited) | Quarter Ended 31-03-2018 (Audited) | Year Ended 31-03-2019 (Audited) | Year Ended 31-03-2018 (Audited) |
| I | (a) Revenue From Operation(Including excise duty) | 239.07 | 1017.90 | 4,630.24 | 3202.78 | 21711.04 |
| II | (b) Other Income | 139.91 | 0.27 | 31.32 | 143.52 | 159.27 |
| III | Total Income (I+II) | 378.98 | 1018.17 | 4,661.56 | 3346.30 | 21870.31 |
| IV | Expenditure | | | | | |
| | Cost of Material Consumed | 6.33 | 273.79 | 10.90 | 757.17 | 7125.99 |
| | Purchase of Stock In Trade | 0.00 | 0.00 | 1,686.83 | 0.00 | 6655.52 |
| | Change in Inventories of Finished Goods, Stock In trade and Work in Progress | 60.10 | (48.85) | 574.96 | (111.15) | 1860.45 |
| | Employee Benefit Expenses | 536.13 | 469.63 | 623.23 | 1994.02 | 2193.49 |
| | Finance costs | 2490.61 | 2443.44 | 2,484.50 | 9605.44 | 9754.26 |
| | Depreciation and Amortisation Expenses | 5520.18 | 463.43 | 618.57 | 6911.93 | 2424.33 |
| | Other Expenditure | 563.09 | 549.66 | 1,251.47 | 2328.39 | 5981.24 |
| | Total Expenses (IV) | 9176.44 | 4151.10 | 7,250.47 | 21485.80 | 35995.28 |
| V | Profit / (Loss) before exceptional items and Tax (I-IV) | (8,797.46) | (3,132.93) | (2,588.91) | (18,139.50) | (14,124.97) |
| VI | Exceptional Items | | | | | |
| VII | Profit / (Loss) before Tax (V-VI) | (8,797.46) | (3,132.93) | (2,588.91) | (18,139.50) | (14,124.97) |
| VIII | Tax Expenses | | | | | |
| | (1) Current Tax | - | - | - | - | - |
| | (2) Deferred Tax | (1601.65) | (608.30) | (478.72) | (3349.06) | (2230.77) |
| IX | Net Profit / (Loss) for the period from continuing operations (VII-VIII) | (7,195.81) | (2,524.63) | (2,110.20) | (14,790.44) | (11,894.20) |
| X | Net Profit / (Loss) for the period from discontinuing operations | - | - | - | - | - |
| XI | Tax expense of discontinuing operations | - | - | - | - | - |
| XII | Net Profit / (Loss) from discontinued operations (after Tax) (X-XI) | - | - | - | - | - |
| XIII | Profit/(loss) for the period (IX+XII) | (7,195.81) | (2,524.63) | (2,110.20) | (14,790.44) | (11,894.20) |
| XIV | Other Comprehensive Income | | | | | |
| | A (i) Item that will not be reclassified to Profit or loss | (21.80) | (1.09) | 58.46 | (25.07) | (5.08) |
| | (ii) Income tax relation to Item that will not be reclassified to Profit or loss | - | - | - | - | - |
| | B (i) Item that will be reclassified to Profit or loss | - | - | - | - | - |
| | (ii) Income tax relation to Item that will be reclassified to Profit or loss | - | - | - | - | - |
| XV | Total comprehensive Income for the period (XIII+XIV)(comprising profit (loss) and other comprehensive income for the period) | (7,217.61) | (2,525.72) | (2,051.74) | (14,815.51) | (11,899.28) |
| XVI | Paid Up Equity share capital(Face value Rs.10/-each) | 2,981.63 | 2,981.63 | 2,981.63 | 2,981.63 | 2,981.63 |
| XVII | Earnings per share (for continuing operation) : | | | | | |
| | (a) Basic | (24.13) | (8.47) | (7.08) | (49.61) | (39.89) |
| | (b) Diluted | (24.13) | (8.47) | (7.08) | (49.61) | (39.89) |
| XVIII | Earnings per share (for discontinued operation) : | | | | | |
| | (a) Basic | - | - | - | - | - |
| | (b) Diluted | - | - | - | - | - |
| XIX | Earnings per share (for discontinued & continuing operation) : | | | | | |
| | (a) Basic | (24.13) | (8.47) | (7.08) | (49.61) | (39.89) |
| | (b) Diluted | (24.13) | (8.47) | (7.08) | (49.61) | (39.89) |



Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing,
Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03;
Fax: (0731) 2401052; E-mail: pdpl@pdindia.com;
CIN: L24100MH1983PLC126481



DRS is Accredited by
JAS-ANZ M50809121F

JAS-ANZ



www.jas-anz.org/register




PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

Statement of Assets and Liabilities (CONSOLIDATED)

| Sr. No. | Particulars | Rs. In Lakhs | Rs. In Lakhs |
|------------|--|---------------------------|---------------------------|
| | | As at 31-03-19 Audited | As at 31-03-18 Audited |
| I. | ASSETS | | |
| (1) | Non-current assets | | |
| | (a) Property, plant and equipment | 35,648.65 | 71,580.42 |
| | (b) Intangible assets | | |
| | (c) Financial Assets | | |
| | (i) Investments | 240.10 | 0.10 |
| | (ii) Loans | 255.50 | 385.84 |
| | (ii) Others | 1.31 | 8.90 |
| | (d) Other non-current assets | 645.63 | 770.69 |
| | (e) Deferred tax Assets(Net) | 10,534.87 | 6,391.48 |
| | Total Non-current assets | 47,326.06 | 79,137.43 |
| (2) | Current assets | | |
| | (a) Inventories | 397.06 | 2,701.43 |
| | (b) Financial Assets | | |
| | (i) Investments | - | - |
| | (ii) Trade receivables | - | 366.48 |
| | (iii) Cash and cash equivalents | 9.53 | 7.64 |
| | (iv) Bank balances ther than (iii) above | 35.10 | 347.22 |
| | (v) Loans | 569.90 | 565.38 |
| | (c) Other Current Assets | 5,719.28 | 5,916.65 |
| | Total Current assets | 6,730.87 | 9,904.80 |
| | Total Assets | 54,056.93 | 89,042.23 |
| II. | EQUITY AND LIABILITIES | | |
| | Equity | | |
| | (a) Equity share capital | 2,981.63 | 2,981.63 |
| | (b) Other Equity | (47,673.76) | (16,625.37) |
| | Total Equity | (44,692.13) | (13,643.74) |
| | Minority Interest | 12.25 | 28.37 |
| (1) | LIABILITIES | | |
| | Non-Current Liabilities | | |
| | (a) Financial Liabilities | | |
| | (i) Borrowings | 10,967.10 | 43,384.78 |
| | (b) Other non-current liabilities | 15.00 | 16.50 |
| | Total Non-Current Liabilities | 10,982.10 | 43,401.28 |
| (2) | Current liabilities | | |
| | (a) Financial Liabilities | | |
| | (i) Borrowings | - | 15,336.10 |
| | (ii) Trade payables | 1,187.19 | 5,119.55 |
| | (iii) Other financial liabilities | 80,695.42 | 36,255.67 |
| | (b) Other current liabilities | 5,034.44 | 1,703.61 |
| | (c) Provisions | 837.66 | 841.39 |
| | Total Current liabilities | 87,754.71 | 59,256.32 |
| | Total Equity and Liabilities | 54,056.93 | 89,042.23 |



Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakh Crossing,
Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03;
Fax: (0731) 2401052; E-mail: pdpl@pdindia.com;
CIN: L24100MH1983PLC126481



DRS is Accredited by
JAS-ANZ M50809121F

JAS-ANZ



www.jas-anz.org/register



PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

Notes to the financial results:

- The above results were reviewed by statutory auditors and audit committee of the company held on 29-05-2019 and approved by Board of Directors in their meeting held on 30-05-2019.
- Additional information on standalone financial results are given below:

| Particulars | Rs. In Lakh | | | | |
|------------------------------|------------------------------------|--------------------------------------|------------------------------------|------------------------------------|------------------------------------|
| | Quarter Ended 31-03-2019 (Audited) | Quarter Ended 31-12-2018 (Unaudited) | Quarter Ended 31-03-2018 (Audited) | Year to Ended 31-03-2019 (Audited) | Year to Ended 31-03-2018 (Audited) |
| Total Income from operations | 378.98 | 1,018.17 | 530.79 | 3,346.30 | 3,431.54 |
| Profit/Loss before tax | (8,797.46) | (3,132.93) | (3,246.30) | (18,139.50) | (11,940.27) |
| Profit/Loss after tax | (7,217.61) | (2,525.72) | (2,668.19) | (14,815.51) | (9,611.53) |

- The above consolidated financial results for the quarter and year ended 31 st March, 2019 have been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable beginning April 1, 2017.
- Pursuant to valuation of the assets (land and building) of erstwhile manufacturing units of the company located at village Asrawad, Indore (MP) and village Bhud, Tahasil Nalagarh, Baddi (HP), the impairment losses for the building situated at Asrawad have been booked for Rs 51.74 crores and for the land located at Asrawad revaluation reserve reduced by Rs. 191.32 crores.
- Figures of quarter ended March 2019 and Year to date do not include the figures of subsidiary company Infotec Healthcare Limited as it has ceased to be a subsidiary w.e.f. 10-07-2018, hence figures are not comparable with previous corresponding period.
- The figures for the quarter ended March 31, 2019 and March 31, 2018 are the balancing figures between audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevant financial year.
- At the moment the Company is having only one reportable segment in accordance with Ind AS 108 (segment reporting) as the business under proposed real estate segment is yet to commence.
- The previous period figures have been regrouped/rearranged wherever found necessary.
- The Consolidated financial results of the Company are available on the web site of the company i.e. www.pdindia.com and on website of the BSE (www.bseindia.com) & NSE (www.nseindia.com)

For & on behalf of the Board of Directors


GOVIND DAS GARG
 DIRECTOR
 DIN 00520067

Place: Indore
Date: 30-05-2019






Independent Auditor's Report on Consolidated Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of Parenteral Drugs (India) Limited

1. We have audited the accompanying Statement of consolidated financial results of Parenteral Drugs (India) Limited (the 'Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as the 'Group'), for the year ended 31 March 2019, being submitted by the Holding Company pursuant to the requirements of Regulation 33 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These consolidated financial results are based on the consolidated financial statements for the year ended 31st March 2019 prepared in accordance with the accounting principles generally accepted in India, including Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 (the 'Act') read with the Companies (Indian Accounting Standards) Rules, 2015, as amended ("Ind AS"), and published consolidated year to date figures up to the end of the third quarter of the financial year prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, Interim Financial Reporting, specified under Section 133 of the Act, and SEBI Circular CIR/CFD/FAC/62/2016 dated 5th July 2016, which are the responsibility of the Holding Company's management. Our responsibility is to express an opinion on these consolidated financial results based on our audit of the consolidated financial statements for the year ended 31st March 2019 and our review of consolidated financial results for the nine-months period ended 31st December 2018.
2. We conducted our audit in accordance with the auditing standards specified under Section 143(10) of the Companies Act 2013. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Parent's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the Parent's internal financial control with reference to the Statement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.
3. In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the reports of other auditors on separate financial statements and on other financial information of the subsidiaries, the consolidated financial results:
 - (i) Includes the financial statements/ consolidated financial statements for the year ended 31st March 2019, of the following entities:
Parenteral Drugs (India) Limited, Parenteral Biotech Limited, Parenteral Impex Limited.
 - (ii) Is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended read with SEBI Circulars CIR/CFD/FAC/62/2016 dated 5 July 2016 in this regard; and
 - (iii) gives a true and fair view in conformity with their recognition and measurement principles laid down in the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated total comprehensive Loss (comprising of net [profit/loss] and other comprehensive income/ loss) and other financial information of the Group for the year ended 31st March 2019.





We did not audit the financial statements / consolidated financial statements of Two subsidiaries, whose financial statements / consolidated financial statements (before eliminating inter company balances) reflect total assets of 159.03 lakhs and net assets of 62.76 lakhs as at 31 March 2019 and total revenues (before eliminating intercompany transactions) of Nil for the year ended on that date, as considered in the consolidated financial results. The consolidated financial results also include the Group's share of net loss (including other comprehensive income) of 0.15 lakhs (before eliminating intercompany transactions) for the year ended 31 March 2019, as considered in the consolidated financial results, whose financial statements / consolidated financial statements have not been audited by us. These financial statements / consolidated financial statements have been audited by other auditors whose reports have been furnished to us by the management and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, and our report in terms of Regulation 33 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular CIR/CFD/FAC/62/2016 dated 5 July 2016, in so far as it relates to the aforesaid subsidiaries, are based solely on the reports of such other auditors.

For Singhal Jain & Co.
Chartered Accountants



Kamal Jain

CA Kamal Jain
(Partner)
M. No. 406604
F.R.N.013995C

Place: Indore
Date: 30.05.2019



PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

Date: 30.05.2019

**To
National Stock Exchange of India Limited,
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai- 400051**

**To
Bombay Stock Exchange Limited
Phiroze Jeebhoy Towers,
Rotund Bldg., Dalal Street,
Mumbai- 400051**

SYMBOL: PDPL

Scrip Code: 524689

Dear Sir/Madam

Sub: Declaration pursuant to Second Proviso to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

DECLARATION

In compliance with the provisions of Regulation 33 (3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, I hereby declare that M/s Singhal Jain & Co., Chartered Accountants, Statutory Auditors of the Company, have issued an Audit Report with an unmodified opinion on Audited Financial Statements of the Company (both Standalone and Consolidated) for the Quarter and year ended 31st March, 2019.

Kindly take the same on record.

Thanking you

for Parenteral Drugs (India) Limited


Govind Das Garg
Whole Time Director
DIN: 00520067

Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing,
Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03;
Fax: (0731) 2401052; E-mail: pdpl@pdindia.com;
CIN: L24100MH1983PLC126481



DRS is Accredited by
JAS-ANZ M5080912IF

JAS-ANZ



www.jas-anz.org/register